Trends in hip fracture epidemiology in Australia: Possible impact of bisphosphonates and hormone replacement therapy

Bone

Volumn 45, Issue 2, 2009, Pages 246-253

  Fisher, A A ^a,b   O'Brien, E D ^a   Davis, M W ^a,b  

^a CANBERRA HOSPITAL   (Australia)

^b The Australian National University   (Australia)

Author keywords

Bisphosphonates; Epidemiology; Hip fracture; Hormone replacement therapy

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN; PROGESTERONE; RISEDRONIC ACID; VITAMIN D;

ADULT; AGE; AGED; ARTICLE; AUSTRALIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PREDICTION; PRESCRIPTION; PREVALENCE; PRIMARY PREVENTION; SEX DIFFERENCE; TREND STUDY;

AGE DISTRIBUTION; AGED, 80 AND OVER; AUSTRALIA; DIPHOSPHONATES; FEMALE; FORECASTING; HIP FRACTURES; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MALE; SEX CHARACTERISTICS;

EID: 67649435983     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.04.244     Document Type: Article

References (92)

1. Cummings S.R., and Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 359 (2002) 1761-1767
2. Jiang H.X., Majumdar S.R., Dick D.A., Moreau M., Raso J., Otto D.D., and Johnston D.W. Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J. Bone Miner. Res. 20 (2005) 494-500
3. Polinder S., Meerding W.J., van Baar M.E., Toet H., Mulder S., and van Beeck E.F. Cost estimation of injury-related hospital admissions in 10 European countries. J. Trauma 59 (2005) 1283-1290 discussion 90-1
4. Vidan M., Serra J.A., Moreno C., Riquelme G., and Ortiz J. Efficacy of a comprehensive geriatric intervention in older patients hospitalized for hip fracture: a randomized, controlled trial. J. Am. Geriatr. Soc. 53 (2005) 1476-1482
5. Johnell O., and Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int. 17 (2006) 1726-1733
6. Sambrook P.N., Chen C.J., March L., Cameron I.D., Cumming R.G., Lord S.R., Simpson J.M., and Seibel M.J. High bone turnover is an independent predictor of mortality in the frail elderly. J. Bone Miner. Res. 21 (2006) 549-555
7. Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., and Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J. Bone Miner. Res. 22 (2007) 465-475
8. Lau E.M., Cooper C., Fung H., Lam D., and Tsang K.K. Hip fracture in Hong Kong over the last decade-a comparison with the UK. J. Public Health Med. 21 (1999) 249-250
9. Schwartz A.V., Kelsey J.L., Maggi S., Tuttleman M., Ho S.C., Jonsson P.V., Poor G., Sisson de Castro J.A., Xu L., Matkin C.C., Nelson L.M., and Heyse S.P. International variation in the incidence of hip fractures: cross-national project on osteoporosis for the World Health Organization Program for Research on Aging. Osteoporos. Int. 9 (1999) 242-253
10. Barbier S., Ecochard R., Schott A.M., Colin C., Delmas P.D., Jaglal S.B., and Couris C.M. Geographical variations in hip fracture risk for women: strong effects hidden in standardised ratios. Osteoporos. Int. 20 (2009) 371-377
11. Cooper C., Campion G., and Melton III L.J. Hip fractures in the elderly: a world-wide projection. Osteoporos. Int. 2 (1992) 285-289
12. Kannus P., Parkkari J., Sievanen H., Heinonen A., Vuori I., and Jarvinen M. Epidemiology of hip fractures. Bone 18 (1996) 57S-63S
13. Gullberg B., Johnell O., and Kanis J.A. World-wide projections for hip fracture. Osteoporos. Int. 7 (1997) 407-413
14. Sanders K.M., Nicholson G.C., Ugoni A.M., Pasco J.A., Seeman E., and Kotowicz M.A. Health burden of hip and other fractures in Australia beyond 2000. Projections based on the Geelong Osteoporosis study. Med. J. Aust. 170 (1999) 467-470
15. Pocock N.A., Culton N.L., and Harris N.D. The potential effect on hip fracture incidence of mass screening for osteoporosis. Med. J. Aust. 170 (1999) 486-488
16. Fisher A., Davis M., Rubenach S., Le Couteur D., and McLean A. The site specific epidemiology of hip fracture in the Australian Capital Territory with projections for the first half of the 21st century: implications for clinical management and health services planning. Australasian Journal on Aging 26 (2007) 45-51
17. Iga T., Dohmae Y., Endo N., and Takahashi H.E. Increase in the incidence of cervical and trochanteric fractures of the proximal femur in Niigata Prefecture, Japan. J. Bone Miner. Metab. 17 (1999) 224-231
18. Kannus P., Niemi S., Parkkari J., Palvanen M., Vuori I., and Jarvinen M. Hip fractures in Finland between 1970 and 1997 and predictions for the future. Lancet 353 (1999) 802-805
19. Reginster J.Y., Gillet P., and Gosset C. Secular increase in the incidence of hip fractures in Belgium between 1984 and 1996: need for a concerted public health strategy. Bull. World Health. Organ. 79 (2001) 942-946
20. Stephenson S., Langley J., Campbell J., and Gillespie W. Upward trends in the incidence of neck of femur fractures in the elderly. N. Z. Med. J. 116 (2003) U665
21. Zingmond D.S., Melton III L.J., and Silverman S.L. Increasing hip fracture incidence in California Hispanics, 1983 to 2000. Osteoporos. Int. 15 (2004) 603-610
22. Hagino H., Katagiri H., Okano T., Yamamoto K., and Teshima R. Increasing incidence of hip fracture in Tottori Prefecture, Japan: trend from 1986 to 2001. Osteoporos. Int. 16 (2005) 1963-1968
23. Beringer T.R., Clarke J., Elliott J.R., Marsh D.R., Heyburn G., and Steele I.C. Outcome following proximal femoral fracture in Northern Ireland. Ulster. Med. J. 75 (2006) 200-206
24. Hernandez J.L., Olmos J.M., Alonso M.A., Gonzalez-Fernandez C.R., Martinez J., Pajaron M., Llorca J., and Gonzalez-Macias J. Trend in hip fracture epidemiology over a 14-year period in a Spanish population. Osteoporos. Int. 17 (2006) 464-470
25. Lonnroos E., Kautiainen H., Karppi P., Huusko T., Hartikainen S., Kiviranta I., and Sulkava R. Increased incidence of hip fractures. A population based-study in Finland. Bone 39 (2006) 623-627
26. Hagino H., Furukawa K., Fujiwara S., Okano T., Katagiri H., Yamamoto K., and Teshima R. Recent trends in the incidence and lifetime risk of hip fracture in Tottori, Japan. Osteoporos. Int. 20 (2009) 543-548
27. Huusko T.M., Karppi P., Avikainen V., Kautiainen H., and Sulkava R. The changing picture of hip fractures: dramatic change in age distribution and no change in age-adjusted incidence within 10 years in Central Finland. Bone 24 (1999) 257-259
28. Rogmark C., Sernbo I., Johnell O., and Nilsson J.A. Incidence of hip fractures in Malmo, Sweden, 1992-1995. A trend-break. Acta. Orthop. Scand. 70 (1999) 19-22
29. Ross P.D., and Huang C. Hip fracture incidence among Caucasians in Hawaii is similar to Japanese. A population-based study. Aging (Milano) 12 (2000) 356-359
30. Balasegaram S., Majeed A., and Fitz-Clarence H. Trends in hospital admissions for fractures of the hip and femur in England, 1989-1990 to 1997-1998. J. Public Health Med. 23 (2001) 11-17
31. Lofthus C.M., Osnes E.K., Falch J.A., Kaastad T.S., Kristiansen I.S., Nordsletten L., Stensvold I., and Meyer H.E. Epidemiology of hip fractures in Oslo, Norway. Bone 29 (2001) 413-418
32. Boufous S., Finch C.F., and Lord S.R. Incidence of hip fracture in New South Wales: are our efforts having an effect?. Med. J. Aust. 180 (2004) 623-626
33. Alvarez-Nebreda M.L., Jimenez A.B., Rodriguez P., and Serra J.A. Epidemiology of hip fracture in the elderly in Spain. Bone 42 (2008) 278-285
34. Melton III L.J., Therneau T.M., and Larson D.R. Long-term trends in hip fracture prevalence: the influence of hip fracture incidence and survival. Osteoporos. Int. 8 (1998) 68-74
35. Fielden J., Purdie G., Horne G., and Devane P. Hip fracture incidence in New Zealand, revisited. N. Z. Med. J. 114 (2001) 154-156
36. Lofman O., Berglund K., Larsson L., and Toss G. Changes in hip fracture epidemiology: redistribution between ages, genders and fracture types. Osteoporos. Int. 13 (2002) 18-25
37. Chang K.P., Center J.R., Nguyen T.V., and Eisman J.A. Incidence of hip and other osteoporotic fractures in elderly men and women: Dubbo Osteoporosis Epidemiology study. J. Bone Miner. Res. 19 (2004) 532-536
38. Jaglal S.B., Weller I., Mamdani M., Hawker G., Kreder H., Jaakkimainen L., and Adachi J.D. Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong?. J. Bone Miner. Res. 20 (2005) 898-905
39. Kannus P., Niemi S., Parkkari J., Palvanen M., Vuori I., and Jarvinen M. Nationwide decline in incidence of hip fracture. J. Bone Miner. Res. 21 (2006) 1836-1838
40. Nymark T., Lauritsen J.M., Ovesen O., Rock N.D., and Jeune B. Decreasing incidence of hip fracture in the Funen County, Denmark. Acta. Orthop. 77 (2006) 109-113
41. Chevalley T., Guilley E., Herrmann F.R., Hoffmeyer P., Rapin C.H., and Rizzoli R. Incidence of hip fracture over a 10-year period (1991-2000): reversal of a secular trend. Bone 40 (2007) 1284-1289
42. Jaglal S. Falling hip fracture rates. J. Bone Miner. Res. 22 (2007) 1098 author reply 99
43. Kanis J.A., McCloskey E.V., Johansson H., Strom O., Borgstrom F., and Oden A. Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos. Int. 19 (2008) 1395-1408
44. MacLean C., Newberry S., Maglione M., McMahon M., Ranganath V., Suttorp M., Mojica W., Timmer M., Alexander A., McNamara M., Desai S.B., Zhou A., Chen S., Carter J., Tringale C., Valentine D., Johnsen B., and Grossman J. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann. Intern. Med. 148 (2008) 197-213
45. Torgerson D.J., and Bell-Syer S.E. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. Jama 285 (2001) 2891-2897
46. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., and Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Jama 288 (2002) 321-333
47. Cauley J.A., Robbins J., Chen Z., Cummings S.R., Jackson R.D., LaCroix A.Z., LeBoff M., Lewis C.E., McGowan J., Neuner J., Pettinger M., Stefanick M.L., Wactawski-Wende J., and Watts N.B. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. Jama 290 (2003) 1729-1738
48. Meyer H.E., Lofthus C.M., Sogaard A.J., and Falch J.A. Change in the use of hormone replacement therapy and the incidence of fracture in Oslo. Osteoporos. Int. 20 (2009) 827-830
49. Cranney A., Guyatt G., Griffith L., Wells G., Tugwell P., and Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr. Rev. 23 (2002) 570-578
50. Wells G., Tugwell P., Shea B., Guyatt G., Peterson J., Zytaruk N., Robinson V., Henry D., O'Connell D., and Cranney A. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr. Rev. 23 (2002) 529-539
51. Watts N.B., Worley K., Solis A., Doyle J., and Sheer R. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J. Manag. Care Pharm. 10 (2004) 142-151
52. Boonen S., Laan R.F., Barton I.P., and Watts N.B. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos. Int. 16 (2005) 1291-1298
53. Liberman U.A., Hochberg M.C., Geusens P., Shah A., Lin J., Chattopadhyay A., and Ross P.D. Hip and non-spine fracture risk reductions differ among antiresorptive agents: evidence from randomised controlled trials. Int. J. Clin. Pract. 60 (2006) 1394-1400
54. Nguyen N.D., Eisman J.A., and Nguyen T.V. Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials. J. Bone Miner. Res. 21 (2006) 340-349
55. Cadarette S.M., Katz J.N., Brookhart M.A., Sturmer T., Stedman M.R., and Solomon D.H. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann. Intern. Med. 148 (2008) 637-646
56. Russell R.G., Watts N.B., Ebetino F.H., and Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 19 (2008) 733-759
57. Beral V. Breast cancer and hormone-replacement therapy in the Million Women study. Lancet 362 (2003) 419-427
58. Watson J., Wise L., and Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur. J. Clin. Pharmacol. 63 (2007) 843-849
59. Boonen S., Vanderschueren D., Venken K., Milisen K., Delforge M., and Haentjens P. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J. Intern. Med. 264 (2008) 315-332
60. Melton III L.J., Kanis J.A., and Johnell O. Potential impact of osteoporosis treatment on hip fracture trends. J. Bone Miner. Res. 20 (2005) 895-897
61. Feldstein A.C., Weycker D., Nichols G.A., Oster G., Rosales G., Boardman D.L., and Perrin N. Effectiveness of bisphosphonate therapy in a community setting. Bone 44 (2008) 153-159
62. Australian Bureau of Statistics. Australian demographic statistics: population projections (catalogue No 3101.0) 2008; Canberra, ACT.
63. Medicare Australia. PBS Statistics [Website]. http://www.medicareaustralia.gov.au/providers/health_statistics/statistical_reporting/pbs.htm.
64. Australian Government Department of Health and Aging. Australian statistics on medicines [1997-2005]. Department of Health and Aging 2007; Canberra.
65. Canfell K., Banks E., Moa A.M., and Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med. J. Aust. 188 (2008) 641-644
66. Armitage P. Theory and practice in medical statistics. Stat. Med. 20 (2001) 2537-2548
67. Gullberg B., Duppe H., Nilsson B., Redlund-Johnell I., Sernbo I., Obrant K., and Johnell O. Incidence of hip fractures in Malmo, Sweden (1950-1991). Bone 14 Suppl 1 (1993) S23-S29
68. Lauritzen J.B., Schwarz P., Lund B., McNair P., and Transbol I. Changing incidence and residual lifetime risk of common osteoporosis-related fractures. Osteoporos. Int. 3 (1993) 127-132
69. Parkkari J., Kannus P., Niemi S., Pasanen M., Jarvinen M., Luthje P., and Vuori I. Increasing age-adjusted incidence of hip fractures in Finland: the number and incidence of fractures in 1970-1991 and prediction for the future. Calcif. Tissue Int. 55 (1994) 342-345
70. Wildner M., and Clark D.E. Hip fracture incidence in east and west germany: reassessement ten years after unification. Osteoporos. Int. 12 (2001) 136-139
71. Ho S.C., Bacon W.E., Harris T., Looker A., and Maggi S. Hip fracture rates in Hong Kong and the United States, 1988 through 1989. Am. J. Public Health 83 (1993) 694-697
72. Finsen V., Johnsen L.G., Trano G., Hansen B., and Sneve K.S. Hip fracture incidence in central norway: a followup study. Clin. Orthop. Relat. Res. 419 (2004) 173-178
73. Koh L.K., Saw S.M., Lee J.J., Leong K.H., and Lee J. Hip fracture incidence rates in Singapore 1991-1998. Osteoporos. Int. 12 (2001) 311-318
74. Giversen I.M. Time trends of age-adjusted incidence rates of first hip fractures: a register-based study among older people in Viborg County, Denmark, 1987-1997. Osteoporos. Int. 17 (2006) 552-564
75. Guilley E., Chevalley T., Herrmann F., Baccino D., Hoffmeyer P., Rapin C.H., and Rizzoli R. Reversal of the hip fracture secular trend is related to a decrease in the incidence in institution-dwelling elderly women. Osteoporos. Int. 19 (2008) 1741-1747
76. Icks A., Haastert B., Wildner M., Becker C., and Meyer G. Trend of hip fracture incidence in Germany 1995-2004: a population-based study. Osteoporos. Int. 19 (2008) 1139-1145
77. Mautalen C.A., Vega E.M., and Einhorn T.A. Are the etiologies of cervical and trochanteric hip fractures different?. Bone 18 (1996) 133S-137S
78. Fisher A., Goh S., Rubenach S., Davis M., McLean A., and Smith P. Clinical and pathophysiological characteristics of different types of osteoporotic hip fracture. Osteoporosis Int. 12 Suppl. 2 (2002) S1-S2
79. Fisher A.A., Davis M.W., Rubenach S.E., Sivakumaran S., Smith P.N., and Budge M.M. Outcomes for older patients with hip fractures: the impact of orthopedic and geriatric medicine cocare. J. Orthop. Trauma. 20 (2006) 172-178 discussion 79-80
80. Holt G., Smith R., Duncan K., Finlayson D.F., and Gregori A. Early mortality after surgical fixation of hip fractures in the elderly: an analysis of data from the scottish hip fracture audit. J. Bone Joint. Surg. Br. 90 (2008) 1357-1363
81. Fransen M., Woodward M., Norton R., Robinson E., Butler M., and Campbell A.J. Excess mortality or institutionalization after hip fracture: men are at greater risk than women. J. Am. Geriatr. Soc. 50 (2002) 685-690
82. Trombetti A., Herrmann F., Hoffmeyer P., Schurch M.A., Bonjour J.P., and Rizzoli R. Survival and potential years of life lost after hip fracture in men and agematched women. Osteoporos. Int. 13 (2002) 731-737
83. Wehren L.E., Hawkes W.G., Orwig D.L., Hebel J.R., Zimmerman S.I., and Magaziner J. Gender differences in mortality after hip fracture: the role of infection. J. Bone Miner. Res. 18 (2003) 2231-2237
84. Hindmarsh D.M., Hayen A., Finch C.F., and Close J.C. Relative survival after hospitalisation for hip fracture in older people in New South Wales, Australia. Osteoporos. Int. 20 (2009) 221-229
85. Cauley J.A., Seeley D.G., Ensrud K., Ettinger B., Black D., and Cummings S.R. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann. Intern. Med. 122 (1995) 9-16
86. Nelson H.D., Humphrey L.L., Nygren P., Teutsch S.M., and Allan J.D. Postmenopausal hormone replacement therapy: scientific review. Jama 288 (2002) 872-881
87. Hundrup Y.A., Ekholm O., Hoidrup S., Davidsen M., and Obel E.B. Risk factors for hip fracture and a possible effect modification by hormone replacement therapy. The Danish nurse cohort study. Eur. J. Epidemiol. 20 (2005) 871-877
88. Lekander I., Borgstrom F., Strom O., Zethraeus N., and Kanis J.A. Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK-results based on the Women's Health Initiative randomised controlled trial. Bone 42 (2008) 294-306
89. Borgstrom F., Johnell O., Kanis J.A., Jonsson B., and Rehnberg C. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos. Int. 17 (2006) 1459-1471
90. Tosteson A.N., Melton III L.J., Dawson-Hughes B., Baim S., Favus M.J., Khosla S., and Lindsay R.L. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos. Int. 19 (2008) 437-447
91. Feldstein A.C., Nichols G., Orwoll E., Elmer P.J., Smith D.H., Herson M., and Aickin M. The near absence of osteoporosis treatment in older men with fractures. Osteoporos. Int. 16 (2005) 953-962
92. Khosla S., Amin S., and Orwoll E. Osteoporosis in men. Endocr. Rev. 29 (2008) 441-464